Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06643767 · ClinicalTrials.gov registry record · NA

Evaluation of the Bexa Breast Examination

A NA study of Breast Cancer, sponsored by Sure.

Recruiting
Registry status
NA
Development phase
500
Enrollment target
1
Study location

NCT06643767: Recruiting NA study of Breast Cancer, sponsored by Sure.

NCT06643767 is a NA study of Breast Cancer that is actively recruiting participants, run by Sure. The registered enrollment target is 500 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06643767, a NA study of Breast Cancer, is actively recruiting participants, sponsored by Sure.

RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
1
Study location

Study Summary

Objective: The "Bexa Breast Exam," or "BBE," for the purposes of this study is defined as the use of a Bexa device in conjunction with a portable, focused ultrasound examination to identify and further evaluate abnormal breast masses including cancer. Commercially, this combination of Bexa plus focused ultrasound is called "Bexa Breast ExamTM," and abbreviated as, "BBE." This study compares the Bexa Breast Exam (BBE) to the standard of care (digital breast tomosynthesis) in detecting masses and as a breast cancer early detection examination. The specific objectives are: 1. To measure the sensitivity and specificity of BBE as compared to digital breast tomosynthesis in the general population of women over 30 without a history of breast cancer. 2. To measure the sensitivity and specificity of BBE as compared to digital breast tomosynthesis identifying breast masses including cancer in women with dense breasts. 3. To demonstrate the proportion of women receiving a BBE that require additional imaging studies. Hypothesis: The purpose of this study is to demonstrate that the Bexa Breast Examination's sensitivity and specificity in identifying abnormal breast masses is comparable to the current accepted standard of care, mammography with tomosynthesis.

Primary Outcome

Bexa sensitivity of mass detection as compared to digital tomosynthesis mammography

Conditions Studied

Interventions

  • DEVICE Bexa and focus ultrasound

Study Locations (1)

Texas

  • Hendrick Health - Vera West Women's Center - Abilene

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-10-16
Est. Completion 2025-05-31
Phase NA
Sure

1 total trials

What NCT06643767 shows while recruiting

NCT06643767 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Bexa and focus ultrasound is the first listed.

NCT06643767 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06643767 about?

NCT06643767 is a clinical study titled "Evaluation of the Bexa Breast Examination". Objective: The "Bexa Breast Exam," or "BBE," for the purposes of this study is defined as the use of a Bexa device in conjunction with a portable, focused ultrasound examination to identify and further evaluate abnormal breast masses including cancer. Commercially, this combination of Bexa plus foc...

What is the current status of trial NCT06643767?

This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2024-10-16. Estimated completion is 2025-05-31.

What conditions does trial NCT06643767 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT06643767?

The interventions under investigation include: Bexa and focus ultrasound (DEVICE).

Who is sponsoring clinical trial NCT06643767?

This trial is sponsored by Sure, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06643767 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06643767's enrollment target sits among peer trials

500 193rd of 1224 higher than 1,022 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06643767, the US trial registry maintained by the National Library of Medicine. NCT06643767 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.